PMID: 7091044Apr 1, 1982Paper

Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry

American Journal of Clinical Oncology
J McCuskerJ M Bennett

Abstract

This study investigated the external validity (or generalizability of results) of randomized clinical trials in cancer. Tao ECOG lung cancer chemotherapy protocols active in the early 1970s were studied using a case-control design. All lung cancer patients of the four specified cell types resident in Monroe County during the ECOG study period were identified from the Rochester Regional Tumor Registry. All of the patients entered into either protocol ("ECOG cases") and a random sample of the nonprotocol cases were examined by medical records review. Thirty-seven percent of the nonprotocol cases were determined to have been eligible for either of the two ECOG protocols, but not entered ("eligible controls"). A comparison of the ECOG cases (n = 65) and the eligible controls (n = 109) revealed that (1) ECOG cases were more likely than eligible controls to have been diagnosed at a hospital which participated in the University of Rochester Cancer Center's medical oncology program; (2) ECOG cases were of higher occupational status than eligible controls; (3) duration from diagnosis to protocol entry for ECOG cases was longer than duration from diagnosis to earliest date of eligibility for eligible controls. The implications of these f...Continue Reading

Citations

Apr 7, 1996·Health Policy·F W Verheggen, F C van Wijmen
Jan 9, 1998·International Journal of Radiation Oncology, Biology, Physics·R M ChamberlainM L Bondy
Sep 30, 2005·American Journal of Respiratory and Critical Care Medicine·Christopher H GossMoira L Aitken
Oct 1, 1990·Controlled Clinical Trials·R B Deber, G G Thompson
Mar 1, 1987·Controlled Clinical Trials·G R LangleyJ E Till
Dec 1, 1987·Controlled Clinical Trials·D B HunninghakeJ L Probstfield
Jun 1, 1985·Controlled Clinical Trials·M E MattsonR McArdle
Jan 1, 1996·International Journal of Technology Assessment in Health Care·J Lumley, H Bastian
Aug 15, 2015·Journal of Comparative Effectiveness Research·David E GerberEthan A Halm
Feb 11, 2015·Journal of the National Cancer Institute·Andrew L LaccettiDavid E Gerber
Sep 26, 2014·Journal of the National Cancer Institute·David E GerberSandi L Pruitt
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen W L YeeLillian L Siu
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Theodore J Iwashyna, Elizabeth B Lamont
Dec 6, 2000·Journal of Clinical Psychopharmacology·A HoferW W Fleischhacker
Oct 1, 1989·Annals of Neurology·M J WingerJ G Cairncross
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Joseph M UngerArchie Bleyer
Dec 30, 2014·Journal of Clinical Psychopharmacology·David L Streiner
Feb 1, 2020·Clinical and Translational Science·Titilayo O IloriTammy Ojo
Jan 1, 1991·Medical and Pediatric Oncology·W B FisherP J Loehrer
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L A SiminoffQ Shen

Related Concepts

Clinical Trials
Decision Making, Shared
Special Hospital
Malignant Neoplasm of Lung
Patient Non-Compliance
Physician's Role
Pilot Projects
Social Role

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.